Basal biomarkers Nestin and INPP4b accurately identify intrinsic breast cancer subtype and predict benefit from anthracycline vs. non-anthracycline based treatment in the CCTG MA. 5 phase III randomized clinical trial Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Asleh, Karama
  • Gao, Dongxia Doris
  • Tu, Dongsheng
  • Shepherd, Lois
  • Levine, Mark Norman
  • Pritchard, Kathleen
  • Nielsen, Torsten

publication date

  • March 2018